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in iMRI-guided resections (n = 33). A greater EOR was 
prognostic for increased progression-free survival (HR 
0.23, p =0.031) and time to re-intervention (TTR) (HR 
0.23, p =0.03). In IDH1 mutant patients, smaller residual 
tumor volumes were associated with increased TTR (HR 
1.01, p =0.03). IDH1 mutation (38/46 cases) was an inde-
pendent positive prognosticator for overall survival (OS) 
in multivariate analysis (HR 0.09, p= 0.002), while exten-
sive surgery had limited impact upon OS. In a subgroup 
of patients with ≥40 % EOR (n = 39), however, initial and 
residual tumor volumes were prognostic for OS (HR 1.03, 
p = 0.005 and HR 1.08, p = 0 07, respectively), persistent 
to adjustment for IDH1. No association between EOR and 
neurologic morbidity was found. In this analysis of low-
grade astrocytomas stratified for IDH1, extensive tumor 
resections were prognostic for progression and TTR and, 
in patients with ≥40 % EOR, for OS.
Keywords Low-grade astrocytoma ·  
Volumetric analysis · Extent of resection · IDH1 · 
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Introduction
Low-grade gliomas (LGGs) represent up to 15 % of all 
primary brain tumors, show a slow but steady growth and 
hold a better prognosis compared to their high-grade coun-
terparts. Nonetheless, their infiltrative behavior into the 
surrounding brain parenchyma imposes a tremendous thera-
peutic challenge. Alongside demographic factors, studies 
have identified preoperative tumor burden and extent of 
resection (EOR) as prognosticators of overall survival (OS), 
progression-free (PFS), or malignant progression-free sur-
vival (MPFS) [1–6]. This puts extensive surgery in favor for 
Abstract Current evidence supports a maximized x ent 
of resection (EOR) in low-grade liomas (LGG), regard-
less of different histological subtypes and molecula  
markers. We therefore evaluated the prognos ic impact of 
extensive, mainly intraoperative (i)MRI-guid d surgery in 
low-grade astrocytomas stratified for IDH1 mutation sta-
tus. Retrospective assessment of 46 c nsecutive cases of 
newly diagnosed supratentorial WHO grade II astrocyto-
mas treated during the last d cade was perfor ed. IDH1 
mutation status was obtained for all patients. Volumetric 
analysis of tumor volumes was performed pre-, intra-, early 
postoperatively and at first follow-up. Survival analysis 
was conducted with uni-and multivariate regressi n mod-
els implementing clinical parameters and continuous volu-
metric variables. Median EOR was 90.4 % (range 17.5–
100 %) and was increased to 94.9 % (range 34.8–100 %) 
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first tumor resection at our department were included into 
survival analysis (n = 46). Retrospective patient selection 
was limited to common availability of digital perioperative 
imaging data since 2004, to allow for volumetric analysis.
Medical charts review was performed including clini-
cal parameters [gender, age at first diagnosis, neurologic 
deficits, Karnofsky Performance Score (KPS)], tumor loca-
tion (side, lobe, eloquence) and treatment history (resec-
tion, radiation, chemotherapy). Only brain regions directly 
associated with motor or speech function were regarded 
eloquent.
Approval from the ethics committee of the University of 
Heidelberg Medical School was obtained prior to conduc-
tion of this retrospective study (reference S-327/2014, as of 
07-03-2014).
Histopathologic review
Histopathologic review confirmed all cases as WHO grade 
II astrocytomas according to the 2007 WHO classification 
[13]. In case of uncertainty, 1p/19q deletion was excluded 
by analysis of genome wide DNA copy number changes as 
previously described [20]. IDH1 mutation status for codon 
R132H was obtained for all cases by immunohistochemis-
try [21] or direct sequencing of the mutation hotspot region 
[22].
Volumetric analysis of EOR
Routine MRI was evaluated at up to four time points in this 
study: preoperatively, early postoperatively (<72 h after 
surgery), at first follow-up (on average 3 months after sur-
gery) and intraoperatively, when applicable (33/46 cases; 
72 %). Imaging sequences contained standard T2-, FLAIR- 
and T1-weighted sequences before and after administration 
of paramagnetic intravenous contrast agent (gadolinium, 
0,1 mmol/kg body weight, single-shot). IMRI was per-
formed at 0.2 T (T) for all procedures until 06/2009 and at 
1.5 T ever since. Pre- and postoperative MRI was performed 
at a field strength of 1.5–3 T.
For volumetric analysis, semi-automatic across-slice 
segmentation with manual correction was performed based 
on signal abnormality on T2/FLAIR-weighted images in 
cm3. Segmentation and volumetric calculation was per-
formed with 3D-Slicer Software on axial slices with adjust-
ment on coronal and sagittal planes, respectively [23]. EOR 
was termed complete (EOR 100 %) if no T2/FLAIR hyper-
intense residual tumor was detected on postoperative imag-
ing. The difference between preoperative tumor volumes on 
T2- and T1-weighted imaging (dT2T1) was calculated as an 
imaging surrogate for infiltrative tumor growth as proposed 
by Skrap et al. [24]. Volumetric data was regarded as a con-
tinuous variable in outcome analysis.
first-line therapy of resectable LGGs, also in case of recur-
rence [1–5, 7–9]. However, achieving a radic l but afe 
tumor resection remains a tightrope walk. In this context, 
intraoperative magnetic resonance imaging (iMRI) offers 
unique possibilities for intraoperative tumor visualization 
with a high potential to augment EOR [5, 10–12].
A critical limitation of pr vious outcome studies in LGG 
surgery is the analysis of survival regardless of different his-
tological subtypes. A pooled analysis of astrocytomas, oli-
godendrogliomas and oligoastr ytomas underrates the fact 
that histology per se conf rs divergent patient survival. In 
fact, WHO grade II astrocytomas show an OS of 5–10 y ars, 
whereas oligodendrogliomas ar  expected to live up to 
5 years longer [13]. Moreover, molecular characteristics 
have recently been shown to refine histological subtypes 
and determine outcome [14–16]. In particular, mutations in 
the isocitrate dehydrogenase 1 (IDH1) enc d ng gen  which 
are present in 70–80 % of LGGs confer a favorable outcome 
in astrocytomas [17] and discriminate lower-grade tumors 
with a rather benign clinic l course from IDH1 wild ype 
(wt) tumors, that molecularly and linically behave like 
glioblastoma [18]. A paradigm shift from a histopathologi  
towards an integrated molecular classification of gliomas 
has ultimately led to a recent update of the WHO classifica-
tion [14, 15, 17–19]. Consequently, when assessing benefits 
of therapeutic interventions such as extensive surgery, strat-
ification for histological subtypes and molecular markers is 
mandatory and facilitates c mparab lity of results.
Apart from that, many surgical outcome studies relied 
on the surgeon’s intraoperative impres ion or gross estima-
tion of EOR instead of objective volumetric measurements 
of residual tumor, which seems increasi gly i app opriate 
given the growing importanc  of EOR in modern glioma 
surgery.
As a lesson learned from the shortcoming  discus ed 
above, we aimed to evaluate the imp ct of extensive, pre-
dominantly iMRI-guided surgery on patient outcome in 
a histologically well-defined cohort of newly diagnosed, 
adult supratentorial WHO grade II astrocytomas eligible 
for tumor resection. In all cases, stratification for IDH1 was 
performed and EOR was determined objectively by volu-
metric analysis pre-, intra- and pos operatively.
Patients and methods
Patient cohort
Out of a consecutive series of 101 adult supratentorial WHO 
grade II gliomas treated by micro-neurosurgical tumor resec-
tion at the Department of Neuros ry, Unive sity Ho pital 
Heidelberg (Germany) from 2004 to 2013, 60 patients with 
pure astrocytic tumors were identified. Only patients with 
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was 35 years (range 17–54 years) with a balanced distribu-
tion between sexes. IDH1 mutations were present in 38/46 
cases (83 %). IDH1 mt and IDH1 wt patients did not differ 
with regard to demographic-, tumor- and treatment-related 
factors except for their respective survival endpoints (Suppl. 
Table 1). Seizures were the most common presenting symp-
tom in 65 % of patients. Median time from first imaging 
diagnosis to surgery was less than 1 month (range 0–91 m). 
Patients were followed up for a median of 70.3 months with 
11 deaths (24 %) recorded meanwhile. More than half of 
the patients (n = 26; 57 %) experienced tumor recurrence or 
progression and 19 patients (41 %) suffered from malignant 
tumor progression. Both consecutive events were recorded 
in 7 patients. Survival data (OS, PFS, MPFS, TTR) are sum-
marized in Table 1.
There was no surgical mortality observed in this cohort. 
KPS was unaltered postoperatively (median KPS: preop-
erative = 100, range 80–100; postoperative = 100, range 
70–100, p = 0.24). Postoperative neurologic deficits were 
rare: 15 % experienced mild transient deficits that ceased 
until hospital discharge and 7 % suffered from mild perma-
nent motor, sensory or speech deficits 3 months after sur-
gery. No patient experienced permanent disabling deficits. 
No significant correlation between EOR and occurrence of 
new postoperative deficits was observed (p = 0.73; Mann–
Whitney test).
Adjuvant treatment after first tumor resection was infre-
quent with 7 patients (15 %) receiving radiotherapy (RT): 
n =3, chemotherapy (CHT): n = 2, or CHT+RT: n = 2. 
Median EOR in patients with adjuvant treatment after first 
tumor resection was significantly lower compared to the rest 
of the cohort (EOR 58.5 %; range 17.5–75.6 %; p = 0.025).
Volumetric analysis of EOR and identification of 
factors influencing tumor resectability
Complete resection (EOR 100 %) was planned in 27 (59 %) 
and achieved in 10 patients (22 %), all of them being per-
formed under iMRI guidance. In the entire cohort (n = 46), 
median preoperative tumor volume was 44.23 cm3 (range 
0.78–193.04 cm3) and was reduced to a median residual 
tumor volume of 4.09 cm3 (range 0–167.98 cm3) on follow-
up MRI. This corresponds to a median final EOR of 90.4 % 
(range 17.5–100 %) (Table 1, Suppl. Table 2; Fig. 1a). In 
cases of iMRI-guided surgery (n = 33), median final EOR was 
further increased to 94.9 % (range 34.8–100 %) and median 
residual volume on follow-up MRI was reduced to 2.99 cm3 
(range 0–108.25 cm3) (Suppl. Table 2; Fig. 1). Triggered by 
delineation of residual tumor on iMRI, additional resection 
was performed in most cases (27/33, 82 %). Final residual 
volumes and EOR were both significantly improved com-
pared to their corresponding iMRI values (p = 0.0001 for 
follow-up vs. intraoperative residual tumor volume and 
Outcome analysis
Outcome parameters were OS, PFS, MPFS and time to re-
intervention (TTR). OS was defined as time from first image 
diagnosis until death or last follow-up. PFS was defined as 
time from first histological diagnosis to radiologic signs of 
progression or malignization based o  the MacD nald/RANO 
criteria, or death [25–27]. MPFS was defined as time from 
first histological diagnosis to radiographic signs of maligniza-
tion [new and treatment-unrela ed contrast nhancement (CE) 
on follow-up MRI], altered histological diagnosis or death. 
Time after initial treatment to any tumor specific re-interven-
tion (surgery, chemotherapy, radiotherapy) was termed TTR. 
Median follow-up at the end of the study (No ember 30, 
2015) was 70.3 months (range 17.5–164.6 m).
Analysis was performed for the full tudy sample (n = 46), 
for IDH1 mutant (mt) patients (n = 38), for all patients with 
≥40 % EOR (n = 39) and for IDH1 mt patients with ≥40 % 
EOR (n = 32). Thereby, we sought to minimize mol cular 
and surgical bias by adjustment for diff ren n tomical 
(tumor size, tumor location, intended partial or complete 
resection) and technical (iMRI) p requisite for su gery 
in this retrospective setting. For subgroup analysis, a 40 % 
EOR cut-off, based on a previ us large volumetri  LGG
study that failed to demonstrate any survival benefit below 
40 % EOR [1–6], sought to discriminat  between extended 
biopsies (<40 % EOR) and tumor resections (≥40 % EOR).
Statistical analysis
Survival associations with mul iple onfound rs were 
analyzed using univariate log-rank tests and multiple Cox 
regression models that included confounders statistically 
significant in univariate analysis. Survival analysis was 
conducted in R (www.r-project. rg). Statistical associations 
between EOR or residual tumor volumes on postoperative 
imaging and potential surgica  and non-surgical confounders 
influencing tumor resectability were investigated by Spear-
man correlation analysis for continuous parameters and 
Mann–Whitney test for binary parameters. Intergroup vari-
ance was evaluated with the nonparametric Mann–Whitney 
test for continuous variables or Wilcoxon’s matched-pairs 
signed rank test for paired observations. Fisher’s exact test 
was used for contingency an lysis using Gra h-Pad Prism 
software (Version 5.0c, Graph Pad Inc., CA, USA).
Results
Patient demographics
Patient demographics including clinical and molecular
parameters are listed in Table 1. Median age at first diagnosis 
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rho = −0.34), incidental finding (Vol epMRI: p = 0.02; EOR 
follow-up MRI: p = 0.02; Vol follow-up MRI: p = 0.001), 
preoperative tumor volumes (Vol epMRI: p = 2.17E–09, 
rho = 0.85; EOR follow-up MRI: p = 0.0001, rho = −0.57; Vol 
follow-up MRI: p = 2.09E–10, rho = 0.82) and iMRI-guided 
EOR, respectively) (Suppl. Table 2; Fig. 1b). Owing to the 
retrospective nature of the study, allocation to iMRI-guided 
or conventional micro-neurosurgical resecti n was not con-
trolled. EOR and residual tumor volumes were significantly 
influenced by patient age (EOR follow-up MRI: p = 0.03, 
n = 46 patients n %
Age at first diagnosis (years; median, range) 35 (17–54)
Sex (female:male) 25:21 54.3:45.7
IDH1 mutation 38 82.6
Follow-up (months; median, range)69 (17.5–164.6)
OS (months; median, range) 119.8 (17.5–164.6)
PFS (months; median, range) 45.1 (4.7–164.6)
MPFS (months; median, range) 81.4 (4.7–164.6)
TTR (months; median, range) 40.9 (4.5–164.6)
Progression 26 56.5
Malignant progression 19 41.3
Death 11 23.9
Seizure as first diagnosis 30 65.2
Time from radiographic diagnosis to surgery  
(months; median, range)
0 (0–91)
KPS pre-op (median, range) 100 (80–100)
KPS post-op (median, range) 100 (70–100)
New permanent neurologic deficits
None 43 93.5
Yes 3 6.5
Tumor eloquence 6 13





Contrast enhancement pre-op14 30.4
dT2T1 (cm3, edian, range) 3.41 (−43.02 to 64.52)




Complete resection planned27 58.7
iMRI employed 33 71.7
Continued resection after iMRI27 (81.8)
Vol. pre-op (cm3; median, range) 44.23 (0.78–193.04)
Vol. iMRI (cm3; median, range) 4.95 (0–143.94)
EOR iMRI (%; median, range) 69.5 (13.3–100)
Vol. epMRI (cm3; median, range) 5.32 (0–113.9)
EOR epMRI (%; median, range) 69.6 (10.9–100)
Vol. follow-up MRI (cm3; median, range)4.09 (0–167.98)
EOR follow-up MRI (%; median, range) 90.4 (17.5–100)
OS overall survival, PFS progression-free survival, MPFS malignant progression-free survival, TTR 
time to re-intervention, KPS Ka nofsky Performance Score, Vol (tumor) volume, iMRI intraoperative 
MRI, epMRI early postoperative MRI, EOR ex ent of resection, dT2T1 volumetric difference of signal 
abnormality between preoperative T2-FLAIR sequences and native T1 sequences
Table 1 Patient demographics
1 3
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tumor volumes on early postoperative or follow-up MRI 
were significantly associated with OS (Table 2). Likewise, 
stratification for EOR thresholds and dichotomization for 
complete (EOR 100 %) and incomplete (EOR <100 %) 
resections each failed to identify a prognostic benefit. To 
exclude a molecular bias, IDH1 mt patients were analyzed 
separately (n = 38). Results coincided however, showing no 
beneficial effect upon OS accountable to surgery (Table 3).
In contrast, excluding patients with <40 % EOR (which we 
considered “open biopsies” rather than “tumor resections”) 
(Suppl. Fig. 1) revealed a strikingly different picture: In this 
subgroup (n = 39) smaller preoperative (HR 1.03; p = 0.005) 
and follow-up residual (HR 1.08; p = 0.007) tumor volumes 
positively impacted on OS. Notably, this effect was main-
tained when only IDH1 mt patients with ≥40 % EOR (n = 32) 
were analyzed (HR 1.09; p = 0.01 for follow-up residual 
surgery (EOR epMRI: p = 0.03; Vol epMRI: p = 0.01; EOR 
follow-up MRI: p = 0.0005; Vol follow-up MRI: p = 0.007) 
(Table 2). Preoperative KPS, IDH1 mut ti n status, pre-
operative dT2T1, preoperative contrast enhancement (CE) 
and tumor location (eloquence, side, lobe) did not impact 
on tumor resectability. In order to rule out that infiltrative 
growth differs between IDH1 mt and IDH1 wt tumors, we 
also investigated a possibl  associati  betw en IDH1 and 
dT2T1 as an imaging surrogate of infiltrative growth, but 
found none (p = 0.8; Mann–Whitney test; Suppl. Table 1).
Confounders of overall survival
Analyzing the entire cohort f WHO grade II astrocytomas 
(n = 46), a universal survival advantage by extensive tumor 
resections was not observed. Neither EOR, nor residual 
Table 2 Confounders of resectability
Volume epMRI Volume follow-up MRIEOR epMRI EOR follow-up MRI
Spearman rhop valueSpearman rhop valueSpearman rhop valueSp arman rhop value
Continuous variables
Age 0.162 0.367 0.264 0.087 −0.184 0.314 −0.338 0.031
Volume preoperative0.845 <0.0001 0.818 <0.0001 −0.338 0.063 −0.572 <0.001
dT2T1 preoperative0.269 0.143 0.159 0.334 −0.008 0.966 −0.057 0.731
Binary variables
KPS preoperative 0.870 0.683 0.917 0.700
Incidental finding 0.024 0.001 0.555 0.019
Tumor eloquence 0.940 0.659 0.917 0.642
IDH1 mutation 0.314 0.208 0.397 0.577
iMRI surgery 0.013 0.008 0.0318 0.001
Analysis of confounders of resectability. Association of continuous variables was assessed by spearman correlation analysis, binary variables 
were analyzed with Mann–Whitney tests. Significant values are presented in bold face
EOR extent of resection, dT2T1 difference in tumor volume expansion on preoperative T2 and T1 sequences, iMRI intraoperative MRI, KPS 
Karnofsky Performance Scale






































Fig. 1  a Volumetric analysis of all surgically treated WHO grade II 
astrocytomas (n = 46). Data is presented in box-plots with medians 
and interquartile ranges preoperatively, on early postoperative MRI 
and on follow-up MRI on average 3 months after surgery. Whiskers 
indicate CI 95 % in cm3. Tumor volumes were smallest on follow-up 
MRI (*p <0.05; paired Mann–Whitney test). b Volumetric analysis of 
iMRI-guided resections (n = 33). Resection was continued after iMRI 
in 82 % of cas s yielding significantly reduced residual tumor volumes 
after surg y (***p = 0.0001; pai ed Mann–Whitney test) 
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surgical radicality (median final EOR > 90 %), in particular 
under iMRI guidance. In survival analysis, a greater EOR 
was prognostic for prolonged PFS and TTR. With respect 
to OS, the anticipated prognostic impact of IDH1 mutation 
status was confirmed while a universal beneficial effect of 
extensive surgery was not observed. Importantly, restricting 
our cohort to patients with tumor resections (≥40 % EOR) 
rather than open biopsies, OS was significantly prolonged 
along with smaller residual tumor volumes.
Current evidence is in favor of a maximized EOR in LGG 
surgery even though most studies rely on combined analysis 
of various histological subtypes regardless of their distinct 
genetic disposition influencing individual patient survival 
[2, 5 28–31]. However, with a paradigm shift from a his-
topathologic towards an integrated molecular classification 
of gliomas, it has become mandatory to stratify for histo-
logical subtypes and molecular markers in modern outcome 
analyses. Our approach to exclusively analyze astrocytomas 
stratified for IDH1 mutation status from a consecutive LGG 
database reflects the effort to minimize biological confound-
ers for surgical outcome analysis and clearly distinguishes 
this series from others published in literature. As a proof of 
concept, IDH1 mutation status was an independent prog-
nosticator for OS in our cohort which is in accordance with 
current literature and underlines the fact that we analyzed a 
representative patient sample [16–18].
A recent analysis of 200 consecutive LGG surgical cases 
demonstrated that IDH1 mutation status, among other 
molecular markers, is independent of EOR, a finding that 
was affirmed by our association study as well. Unfortunately, 
Cordier et al. did not provide imaging data that would allow 
conclusions on a direct link between radiographic growth 
patterns (e.g. infiltrative vs. circumscribed) and the underly-
ing molecular phenotype, ultimately translating into tumor 
resectability [32]. Metellus et al. found IDH1 wt tumors to 
exhibit a more infiltrative phenotype on MRI compared to 
volume). The Kaplan–Meier plot n Fig. 2a depicts a stepwis  
prolongation of OS through re uced postoperative tumor 
burden. In the latter subgroup (≥40 % EOR/IDH1 mt), deaths 
were registered only in the bottom quartiles of atients with 
largest residual tumor volume fter surgery (p = 0.0395).
The anticipated prognostic impact of IDH1 mutation s a-
tus was affirmed by a prolongation of OS in IDH1 mt patients 
in multivariate analysis (HR 0.09; 95 % CI 0.02–0.42; 
p =0.002, Suppl. Table 3; Fig. 2b). Interesting y, adjuvant 
treatment at first histological diagnosis was an independent 
prognosticator as well and was associated with inferior OS 
(HR 7.13; 95 % CI 1.92–26.52; p = 0.003, Suppl. Table 3).
Confounders of (malignant) progression-free surviv l 
and time to re-intervention
In contrast to OS, IDH1 mutation status did not impact on 
PFS, MPFS and TTR. However, these outcome par m-
eters were significantly affected by extensive surgery. With 
respect to follow-up MRI, EOR w s prognos ic for PFS 
(HR 0.23; p =0.031) and TTR (HR 0.23; p = 0. 3), with a 
complete resection (EOR 100 %) also being prognostic for 
a superior TTR (HR 0.28; p = 0.029) (Table 3). In IDH1 mt 
patients, TTR was increased along with smaller residual 
tumor volumes at follow-up MRI (HR 1.01; p = 0.03). dT2T1 
was another prognosticator of PFS (HR 1.03; p = 0.028), a 
finding that was most pronounced in the subgroup of resect-
able tumors (≥40 % EOR/IDH1 mt) (Table 3).
Discussion
This study sought to evalu e the progno tic impact of 
extensive surgery in a histologically well-defined cohort of 
WHO grade II astrocytomas stratified for IDH1 mutation 











































Fig. 2 a Kaplan–Meier plot for OS in the subgroup of IDH1 mt 
patients with ≥40 %EOR. Events occur only in the bottom quartiles of 
patients with largest residual tumor volumes after surgery (Q1 = small-
est residual volumes, Q4 = argest residual volumes on follow-up MRI) 
(HR 4.2; 95 % CI 0.9–19.62;  = 0.0395). b Kaplan–Meier plot depict-
ing OS stratified for IDH1 mutations in WHO grade II astrocytomas. 
IDH1 mt patients (blue lin) had significantly uper or OS compared 
to IDH1 wt patients (red line) (HR 0.09; 95 % CI 0.02–0.42; p = 0.002)
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was not at the expense of additional neurologic morbid-
ity. It must be admitted, however, that the percentage of 
tumors located within eloquent regions (13 %) was rather 
low compared to literature [42]. Since this is a retrospective 
analysis, we cannot rule out that some surgeons might have 
been reluctant to offer extensive surgery in case of involve-
ment of presumed eloquent areas and this has reduced the 
number of eloquent tumors considered for resection in our 
cohort. Moreover, among the inconsistent definitions of 
“eloquence” in the literature, leading to a highly variable 
percentage of “eloquent tumors”, only brain regions directly 
associated with motor or speech function were regarded elo-
quent in this study while functional areas related to e.g. sen-
sory function and vision were disregarded.
With respect to OS, our analysis failed to observe a uni-
versal survival advantage conferred by extensive surgery, 
in contrast to larger surgical outcome studies [1, 2, 4]. Even 
though a molecular bias could be accused to override pos-
sible benefits of surgery on patient outcome, analyzing IDH 
mt patients only did not turn EOR or residual tumor vol-
umes into prognosticators for OS either. This finding may 
be explained by compiling our patient sample based on 
histological rather than surgical criteria. Hence, our cohort 
included a broad range of preoperative tumor volumes 
(0.78–193.04 cm3) with heterogeneous tumor locations, 
likely resulting in divergent surgical goals that ranged from 
extended biopsy to complete resection and ultimately led to 
an EOR ranging from of 17.5 to 100 % on follow-up MRI. 
To minimize surgical bias caused by different surgical pre-
requisites, we sought to preclude all patients with extended 
biopsies rather than tumor resections from further survival 
analysis. The cut-off was set at 40 % EOR, incorporating 
evidence from a large volumetric LGG series that failed to 
demonstrate any survival benefit below a 40 % EOR cut-off 
[2] since our own study sample was too small to identify 
an EOR threshold with prognostic impact. This maneuver 
erased seven tumors with a high median preoperative vol-
ume of 134 cm3 from outcome analysis, including four of 
the six largest tumors in our study sample (Suppl. Fig. 1). 
In the remaining subgroup of patients with an EOR ≥40 % 
(n = 39), preoperative and follow-up MRI residual tumor 
volumes eventually showed a significant impact on OS. 
This finding supports previous studies reporting that not 
only relative EOR but in particular absolute residual tumor 
burden affects outcome [2, 9].
Interestingly, only EOR and residual tumor volumes 
depicted on first follow-up, but not on early postopera-
tive MRI predicted patient outcome. Following imaging 
protocols for HGG, the amount of residual tumor is com-
monly assessed on early postoperative MRI in LGG as well, 
albeit any sustainable evidence [43]. However, Belhawi et 
al. previously illustrated how postoperative signal altera-
tions caused by post-resection injury can particularly bias 
IDH1 mt counterparts [33]. Ius et al. proposed the differ-
ence between tumor expansion on T2- and T1-weigh ed pre-
operative MRI (dT2T1) as an imaging surroga  paramete  
of infiltrative growth in LGG that also proved to be predic-
tive of EOR and PFS in two rece t studies [3, 24]. In our 
analysis, a higher dT2T1 (i.e. more infiltrative radiographic 
growth pattern) was negatively associated with PFS as well. 
However, our data provide no evidence for a significant 
association between dT2T1 and EOR residual umor
volumes on the one hand and dT2T1 and IDH1 mu ation 
status on the other hand. Ev n thou h IDH mutations are 
early events in the formation f LGGs, their r le in glioma-
genesis is not particularly linked o invasiveness of tumor 
cells but rather to aberrant cellular metabol m resulting in 
oncometabolites. Thus, the molecular phenotype nderlying 
the prognostic impact of dT2T1 needs to be further defined 
[34, 35].
Instead, EOR and residual tumor volumes were signifi-
cantly associated with preop ra ive tumor burden, incidental 
finding, patient age and iMRI-guided surgery. Consequently, 
multivariate survival analysis was adjusted for these signifi-
cant confounders of resectability. Th  high surgical radical-
ity observed in our iMRI subgroup should encou age the 
use of iMRI, considering recent m lticenter data in favor of 
high-field iMRI for GTR in LGG surgery [31]. It has to be 
kept in mind, however, that the uncontrolled application of 
iMRI in our study does not provide vidence for superiority 
of iMRI over conventional surgery. Our results are also in 
line with previous findings that smaller preoperative tumor 
volumes and incidentally discovered LGGs (possibly due to 
smaller tumor size and non-el quent tumor loc tion) confer 
a higher EOR and are also consider d prognostic factors [9, 
36–39]. Indeed, in our series, preoperative tumo  volumes 
were significantly smaller in patients with complete resec-
tions (100 % EOR; n = 10) compared to the re t of the c hort 
(median preoperative tumor volume: 5.6 cm3 (range 0.78–
47.2 cm3) vs. 56.7 cm3 (range 8.7–193.04 cm3); p = .004, 
Mann–Whitney test) but this did not transla e into a survival 
benefit in multivariate analysis. Thus, we cannot extrapolate 
from our data that the beneficial outcome associated with 
increased EOR is independent of tumor size as  tum r-
intrinsic confounder of resectability. Much larger studies are 
needed to clarify this issue.
In volumetric analysis, we obse ved a median EOR as 
high as 90 % in our cohort and, consequently, anticipated a 
beneficial impact of extensive surgery on patient outcome. 
Indeed, greater EOR was a posit ve pr gnosticator f PFS 
and TTR. Importantly, when analyzing IDH1 mt patients 
only, TTR was significantly increased along with smaller 
residual tumor volumes. This finding offers the prospect for 
long-lasting disease contro  through rgical int rvention 
regardless of molecular markers and might a so impact on 
quality of life [1, 8, 40, 41]. In our cohort, a greater EOR 
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markers and illustrates the diverse impact of biological and 
surgical confounders upon patient survival.
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